Status:
UNKNOWN
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Collaborating Sponsors:
Anyang Regional Hospital
Huaihe Hospital of Henan University
Conditions:
ST Segment Elevation Myocardial Infarction
Primary Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Primary percutaneous coronary intervention (PPCI) is the gold standard of treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following PPCI in STEMI patie...
Eligibility Criteria
Inclusion
- Ischemic symptoms \< 12h, or evidence of ongoing ischemia 12h after symptom onset
- Continued ischemic chest pain \> 30min
- ST-segment elevation ≥ 0.1 millivolt in 2 or more contiguous leads on the 12-lead ECG or new left bundle branch block (LBBB)
- Detection of a rise of cardiac biomarker values with at least one value above the 99th percentile upper reference limit (URL)
- Primary coronary artery angiography was planned.
Exclusion
- Emergency thrombolytic therapy was performed before primary coronary artery angiography
- Cardiogenic shock with no response to hypervolemic treatment or vasopressor
- Severe cardiomyopathy or valvular disease requiring intervention
- Coronary ectasia
- Severe heart failure
- Contraindication or allergy to antiplatelet drugs
- Contraindication or allergy to experimental drugs
- Unable to receive at least 1 year of dual antiplatelet therapy
- Active bleeding or extreme-risk for major bleeding
- Severe liver or renal failure
- Life expectancy \< 1 year
- Unable or unwilling to provide informed consent
- Women of child bearing potential
- Under 18 years of age
- Hemoglobin \< 90g/L
- Platelet count \< 100×10\^9/L
- Can not cooperate (with mental disorders or cognitive disorders)
Key Trial Info
Start Date :
January 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03406819
Start Date
January 7 2018
End Date
December 31 2019
Last Update
January 23 2018
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Anyang District Hospital
Anyang, Henan, China, 455000
2
The 99th Central Hospital of the People's Liberation Army
Jiaozuo, Henan, China, 454000
3
The People's Hospital of Jiaozuo
Jiaozuo, Henan, China, 454002
4
The second people's Hospital of Jiyuan
Jiyuan, Henan, China, 454000